Authors
P García, M González Fernández, MN Rivas, J Duruelo, E Garmendia, J Arostegui Lavilla, F Perez-Ruiz, A Alonso, C Modesto, BA Blanco Cáceres
Publication date
2020/6/1
Source
Annals of the Rheumatic Diseases
Volume
79
Issue
Suppl 1
Pages
1468-1468
Publisher
BMJ Publishing Group Ltd
Description
Background
Immunogenicity against adalimumab leads to loss of response and secondary failure to biologic therapy; however, concomitant use of methotrexate (MTX) seems to reduce the development of anti-drug antibodies (ADAbs) in a dose-dependent manner. Suboptimal adherence to MTX may favour ADAbs appearance.
Objectives
To evaluate the relationship between MTX adherence and ADAbs development.
Methods
Observational study among adult patients with chronic inflammatory arthropathy, followed in a tertiary care centre, who were in treatment with MTX and adalimumab. ADAbs formation in relation to MTX adherence was assessed.
Results
33 patients were included, with a MTX adherence overall mean of 82.13 (12.45%-100%, median adherence 92.19%). Only 9.09% (n=3) of the patients developed ADAbs, being its MTX adherence mean of 60.95% (46.47%-70%, median adherence 66.39 …
Scholar articles
P García, MG Fernández, MN Rivas, J Duruelo… - 2020